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Objectives: The objective of this study was to investigate the evolution of resistance to antimicrobials, corre-
sponding mechanisms and molecular characteristics of Staphylococcus spp., between 1999 and 2014.
Methods: Susceptibility to 38 antimicrobials was determined for 632 clinical staphylococcal isolates obtained
from companion animals (dogs, cats, horses and other animals). Twenty antimicrobial resistance genes, includ-
ing mecA and mecC, were screened by PCR. Methicillin-resistant staphylococci were characterized by spa
(Staphylococcus aureus), SCCmec, MLST and PFGE typing. Statistical analyses were performed using SAS v9.3
and differences were considered relevant if P≤0.05.
Results: The mecA gene was identified in 74 staphylococcal isolates (11.6%): 11 MRSA (40.7%), 40 methicillin-
resistant Staphylococcus pseudintermedius (MRSP; 8.7%) and 23 methicillin-resistant CoNS (26.7%). Resistance
to the majority of antimicrobials and the number of mecA-positive isolates increased significantly over time.
Eighteen spa types were identified, including two new ones. MRSA isolates were divided into three PFGE clusters
that included ST22-IV, ST105-II, ST398-V and ST5-VI. Most methicillin-resistant Staphylococcus epidermidis iso-
lates were of clonal complex (CC) 5, including a new ST, and clustered in eight PFGE clusters. MRSP were grouped
into five PFGE clusters and included ST45-NT, ST71-II-III, ST195-III, ST196-V, ST339-NT, ST342-IV and the new
ST400-III. Methicillin-resistant Staphylococcus haemolyticus clustered in two PFGE clusters.
Conclusions: The significant increase in antimicrobial-resistant and mecA-positive isolates in recent years is
worrying. Furthermore, several isolates are MDR, which complicates antimicrobial treatment and increases the
risk of transfer to humans or human isolates. Several clonal lineages of MRSA and methicillin-resistant
S. epidermidis circulating in human hospitals and the community were found, suggesting that companion ani-
mals can become infected with and contribute to the dissemination of highly successful human clones. Urgent
measures, such as determination of clinical breakpoints and guidelines for antimicrobial use, are needed.
Introduction
Staphylococci are a group of bacteriawith clinical, veterinary, agri-
cultural and economic importance because of their wide range of
virulence factors and ability to become resistant to antimicrobials.
This feature should be considered and antimicrobial susceptibility
testing is important to monitor the spread of antimicrobial-
resistant staphylococci.1 Therefore, monitoring programmes
may help uncover new resistance trends and evaluate the useful-
ness of the available antimicrobials against staphylococci.
Companion animals, in particular, are frequently treated with
the same antimicrobial classes used in human medicine.2,3
The genus Staphylococcus causes a different array of infections
and the most common species in companion animal practice
are the coagulase-positive Staphylococcus pseudintermedius
(formerly called Staphylococcus intermedius), Staphylococcus
schleiferi and Staphylococcus aureus. These are mostly found in
skin samples, ear samples and as the cause of urinary tract infec-
tions (UTIs).1 CoNS, on the other hand, are usually not considered
pathogenic, although they are often considered reservoirs of anti-
microbial resistance genes, e.g. the mecA gene.4 Presence of the
mecA or mecC genes is one of the most significant features
encountered in staphylococcal species. These genes mediate
resistance to b-lactams, which are first-line antimicrobial choices
for the treatment of infections in human and veterinary medicine
and are considered by theWHO as ‘critically important’ antimicro-
bials.5 Furthermore, knowledge on the genotype of such isolates is
important to assess the risk of transfer of methicillin-resistant
staphylococcal isolates between companion animals and
humans.
# The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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The main objective of this study was to investigate the trends in
antimicrobial resistance in clinical staphylococci isolated from com-
panion animals overa 16 year period (1999–2014). Furthermore,we
identified the genetic mechanisms underlying the antimicrobial
resistance. Finally, we characterized the genotypes of themethicillin-
resistant staphylococci to understand evolutionary steps driving the
spread of these isolates in companion animals.
Materials and methods
Isolate collection
Six hundred and thirty-two staphylococcal isolates obtained from com-
panion animals between 1999 and 2014 were included in the study. The
isolateswere collected at the Clinical Laboratory and the Antimicrobial and
Biocide Resistance Laboratory, FMV-UL, which receive samples from the
Veterinary Teaching Hospital of FMV-UL and private practices throughout
the Lisbon region. The isolates were obtained from clinical infections and
sent to the laboratory along with a small form including animal data, such
as species, breed, age and sex, clinical description of the sample site and
suspected pathology course. Each isolate was considered individually and
cases where more than one isolate originated from the same animal (i.e.
different staphylococci isolated at the same time from the same specimen
or at different sampling times) were considered only if the staphylococcal
species or genotype differed between isolates.
Staphylococcal species identification
Both the Clinical Laboratory and the Antimicrobial and Biocide Resistance
Laboratory use phenotypic tests (BDTM BBLTM Crystal Gram Positive ID Kit;
Becton, Dickinson and Company, MD, USA) to determine the staphylococcal
species. All species were confirmed by PCR (Staphylococcus epidermidis-
specific primers Se705-1/Se705-2, Staphylococcus saprophyticus-specific
primers Sap1/Sap2, Staphylococcus xylosus-specific primers XYL F/XYL R
and Staphylococcus simulans-specific primers SimF/SimR)6–10 and/or
sequencing of the 16S rRNA gene. The sequences were compared using
the nucleotide basic local alignment search tool (http://blast.ncbi.nlm.nih.gov/).
Antimicrobial susceptibility testing
All isolates were tested by disc diffusion according to CLSI standards and
S. aureus ATCC 29213 was used for quality control purposes whenever a
new antimicrobial batch was used.11 A total of 38 antimicrobials (Oxoid,
Hampshire, UK) was tested: amikacin (30 mg), ampicillin (10 mg), amoxicil-
lin/clavulanic acid (30 mg), cefalotin (30 mg), cefotaxime (30 mg), cefovecin
(30 mg), cefoxitin (30 mg), ceftriaxone (30 mg), chloramphenicol (30 mg),
ciprofloxacin (5 mg), clindamycin (2 mg), enrofloxacin (5 mg), erythromycin
(15 mg), florfenicol (30 mg), fusidic acid (10 mg), gentamicin (10 mg), kana-
mycin (30 mg), levofloxacin (5 mg), linezolid (30 mg), moxifloxacin (5 mg),
mupirocin (5 mg), neomycin (30 mg), netilmicin (30 mg), nitrofurantoin
(300 mg), norfloxacin (10 mg), ofloxacin (5 mg), oxacillin (1 mg), penicillin G
(10 U), quinupristin/dalfopristin (15 mg), rifampicin (5 mg), streptomycin
(15 mg), sulphonamides (300 mg), teicoplanin (30 mg), tetracycline
(30 mg), tobramycin (10 mg), trimethoprim (5 mg), trimethoprim/sulfa-
methoxazole (25 mg) and vancomycin (30 mg). Some antimicrobials were
included since they are clinically relevant antimicrobial agents and others
were included for antimicrobial resistance epidemiology purposes (e.g. line-
zolid, quinupristin/dalfopristin and teicoplanin). Results were interpreted
according to CLSI VET01-S212 (oxacillin for S. pseudintermedius, enrofloxa-
cin, gentamicin and clindamycin), CLSI M100-S2413 (ampicillin, penicillin,
cefoxitin for S. aureus and CoNS, teicoplanin, amikacin, kanamycin, netil-
micin, tobramycin, erythromycin, tetracycline, ciprofloxacin, levofloxacin,
norfloxacin, ofloxacin, moxifloxacin, nitrofurantoin, trimethoprim/sulfa-
methoxazole, sulphonamides, trimethoprim, chloramphenicol, rifampicin,
quinupristin/dalfopristin, linezolid), CA-SFM VET-1014 (neomycin) and
CA-SFM 1015 (streptomycin and mupirocin). EUCAST guidelines16 were
used for fusidic acid interpretation. Breakpoints for amoxicillin/clavulanic
acid, cephalosporins and vancomycin were recently removed from CLSI
guidelines. However, as these antimicrobials were included in the suscep-
tibility panel of both laboratories, we used the breakpoints given by the last
CLSI document containing them (CLSI M100-S1617 and CLSI M100-S2218).
The breakpoints (mm) for cefovecin were retrieved from the manufacturer
(S≥24, I 21–23 and R≤20). There are no breakpoints for florfenicol against
staphylococci and we assessed the distribution of the zone diameters
(mm) detected in our study (Figure S1, available as Supplementary data
at JAC Online), estimating a resistance breakpoint of R,19. A bacterial iso-
latewas consideredMDRwhen it exhibited resistance to three ormore anti-
microbial classes.19 Isolates with intermediate susceptibility were regarded
as susceptible.
Detection of antimicrobial resistance genes
The presence of themecA andmecCgeneswas tested in all staphylococcal
isolates. Other antimicrobial resistance geneswere investigated onlywhen
phenotypic resistance was observed. Genes previously reported for resist-
ance to b-lactams (blaZ), aminoglycosides (aadE, aadD, aphA3 and
aacA-aphD), macrolides/lincosamides [erm(A), erm(B), erm(C), msrA and
mph(C)], tetracyclines [tet(M) and tet(K)], fusidic acid (fusB and fusC),
chloramphenicol (cat pC221), florfenicol (fexA) and trimethoprim [dfr(G)
and dfr(K)] were detected by PCR.20,21
Molecular characterization
All S. aureus isolates were subjected to spa typing and spa types were
assigned through the Ridom web server (http://www.ridom.de/spaserver/).
MLSTwas performed on theMRSA,methicillin-resistant S. pseudintermedius
(MRSP; representative isolates determined by PFGE) andmethicillin-resistant
S. epidermidis (MRSE) isolates (http://www.mlst.net/databases/default.asp;
http://pubmlst.org/databases/). SCCmec types were determined as described
previously.22 Themethicillin-resistant staphylococcal isolateswere compared
by SmaI-PFGE using previously described protocols.21–23 PFGE clusters were
defined when the isolates had ≥80% similarity.
Statistical analyses
Statistical analyses were performed with SAS software version 9.3 (SAS
Institute, Cary, NC, USA) and results were considered significant when
P≤0.05. For the purpose of statistical analyses, we defined staphylococcal
species as S. aureus, S. pseudintermedius, S. schleiferi and CoNS. The asso-
ciation between staphylococcal species, antimicrobial resistance and
resistance genes was assessed using either the x2 test or Fisher’s exact
test (when n≤5).
The importance of animal species (dog or cat), type of infection (pyo-
derma, UTI or otitis) and age within animal species as possible risk factors
for resistance to the different antimicrobials was analysed by logistic
regression, considering each factor individually.
The evolution over time of the proportion of isolates resistant to differ-
ent antimicrobials was analysed by logistic regression, using year as the
independent variable. This test was also used to determine whether
there was a significant increase in the proportion of mecA-positive isolates
over time.
Results
This research study involved a total of 632 staphylococcal isolates
from 614 animals, of which 537 isolates were from dogs (87.4%),
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animals (0.8%). Overall, 252 isolates were from females (41.0%),
346 from males (56.4%) and 34 were unknown (5.5%). The aver-
age age was 6.8 years for dogs, 5.5 for cats and 11.4 for horses.
Isolatesweremost frequently isolated fromotitis (307 isolates,
48.6%), followed by 178 isolates from pyoderma (28.2%), 90 from
UTI (14.2%), 10 from surgical site infections (1.6%) and 47 from
other types of infection (7.4%). The frequency of each staphylo-
coccal species is shown in Table 1, with a clear predominance of
S. pseudintermedius, with 446 isolates (70.6%), followed by CoNS
species with 86 isolates (13.6%), S. schleiferi with 73 isolates
(11.6%) and 27 isolates of S. aureus (4.3%).
The frequencies of antimicrobial resistance and antimicrobial
resistance genes are shown in Tables 2 and 3, respectively. All
isolates were susceptible to vancomycin, teicoplanin, linezolid,
netilmicin and quinupristin/dalfopristin. About 35%of the staphylo-
coccal isolates were MDR. The mecA gene was identified in 74
staphylococcal isolates (11.6%): 11 S. aureus (40.7%), 40 S. pseu-
dintermedius (8.7%) and 23 CoNS (26.7%) (Table 3). None of the
isolates carried the mecC gene. We detected the fexA gene in
three isolates that were resistant to florfenicol and chlorampheni-
col (one S. aureus and two S. pseudintermedius). In these
fexA-positive isolates, we searched for the cfr gene and detected,
for the first time, the cfr gene in an S. pseudintermedius isolate
(confirmed by sequencing).
The CoNS and S. aureus isolates had higher probabilities of hav-
ing the mecA gene (P,0.0001) than S. pseudintermedius or S.
schleiferi (40.7% and 26.7% versus 8.7% and 0%, respectively;
Table 3). Resistance to ampicillin/penicillin and the presence of
the blaZ gene were highly associated with both S. aureus and S.
pseudintermedius (P,0.001; Tables 2 and 3, respectively). S. aureus
weremore resistant to fluoroquinolones [enrofloxacin (P,0.0001),
ciprofloxacin (P,0.0001), levofloxacin (P,0.0001), norfloxacin
(P,0.0001), ofloxacin (P,0.0001) and moxifloxacin (P,0.0001)]
than the other species (Table 2). S. pseudintermedius were more
likely (P,0.05) to have the erm(B) gene and less likely (P,0.05)
to have the erm(C) gene than any other species (Table 3).
Streptomycin resistance was more associated with S. pseudinter-
medius (P,0.02; Table 2) and the aadE gene was only present in
this species (Table 3). On the other hand, tetracycline resistance
was associated with CoNS (P,0.02) and S. pseudintermedius
(P,0.0003; Table 2), with the tet(K) gene more associated with
CoNS (P,0.006) and the tet(M) gene with S. pseudintermedius
(P,0.0001; Table 3). Resistance to fusidic acid was higher in the
CoNS isolates (P,0.02; Table 2).
The variables gender and age were not considered risk factors
(P.0.05) leading to more antimicrobial resistance. However, iso-
lates from dogs were resistant to more antimicrobials (Table 4)
than isolates from cats (P,0.05). Likewise, staphylococcal
isolates from otitis were resistant to more antimicrobials than
isolates from pyoderma or UTI (P,0.05; Table 4). No significant
differences were found between isolates from pyoderma and
isolates from UTI (P.0.05).
Using logistic regression analysis, we assessed trends over time in
the resistance to the different antimicrobials. Among the 38 antimi-
crobials analysed, resistance increased over the period analysed
(P,0.05) in 27 antimicrobials (Figure 1) and the number of isolates
with resistance to at least one antimicrobial or withmultidrug resist-
ance also increased over time (P,0.05; Figure 1). The number of
mecA-positive isolates also increased over time (P,0.05; Figure 2).
The antimicrobials where resistance did not increase significantly
(P.0.05) over the 16 year period under analysis were amikacin, flor-
fenicol, fusidic acid, mupirocin, nitrofurantoin and rifampicin. The
corresponding OR, CI and P values are given in Table S1.
The characteristics of all methicillin-resistant staphylococcal
isolates are shown in Table S2. Eighteen spa types were identified
in S. aureus (t002, t025, t032, t044, t084, t085, t091, t105, t108,
t148, t311, t1294, t1346, t1897, t2357 and t11188), including
two new spa types (t14112 and t14113). The MRSA isolates
were divided into three PFGE clusters (Figure S2) and MLST
included ST22-IV (n¼8, including t025, t032 and t2357),
ST105-II (n¼1, t002), ST398-V (n¼1, t108) and ST5-VI (n¼1,
t311). Isolates ST5 and ST105 belonged to clonal complex (CC) 5.
Most MRSE isolates were members of CC5: ST2-NT (n¼2),
ST5-NT (n¼2), ST20-NT (n¼1), ST23-IV (n¼1), ST35-NT (n¼1),
ST57-IV (n¼1), ST190-NT (n¼1) and a new ST (n¼1), which
carried an SCCmec II. The MRSE isolates were divided into eight
PFGE clusters (Figure S2), with the two MRSE ST2 isolates having
,80% similarity by PFGE.
MRSP were grouped into five PFGE clusters (Figure S2) and
included ST45 (n¼1), ST71 (n¼13), ST195 (n¼1), ST196 (n¼1),
ST203 (n¼1), ST339 (n¼1), ST342 (n¼2) and a new ST, assigned
ST400 (n¼3). ST71, ST195 and ST203 belonged to CC71, while
ST342 belonged to CC261, ST45 to CC45, ST196 to CC196 and
ST339 to CC84. The isolates for which MLST was not performed
grouped in the same PFGE cluster and thus we assumed they
belonged to CC71. The MRSP ST45 strain was non-typeable by
SCCmec typing and SmaI-PFGE macrorestriction.
Methicillin-resistant Staphylococcus haemolyticus were divided
into two PFGE clusters (Figure S2) and SCCmec V (n¼5) was the
most frequent type, followed by NT (n¼3).
Discussion
Recent studies have evaluated antimicrobial resistance in S. pseu-
dintermedius.2,24,25 However, none of these studies combined all






S. aureus 27 (4.3) 11 (40.7)
S. caprae 1 (0.2) 1 (100)
S. cohnii 2 (0.3) 0 (0.0)
S. epidermidis 20 (3.2) 11 (55.0)
S. felis 26 (4.1) 0 (0.0)
S. haemolyticus 13 (2.1) 8 (61.5)
S. hominis 1 (0.2) 1 (100)
S. kloosi 1 (0.2) 0 (0.0)
S. lentus 2 (0.3) 1 (50.0)
S. lugdunensis 1 (0.2) 0 (0.0)
S. pseudintermedius 446 (70.6) 40 (8.7)
S. saprophyticus 4 (0.6) 0 (0.0)
S. schleiferi 73 (11.6) 0 (0.0)
S. simulans 9 (1.4) 1 (11.1)
S. warneri 3 (0.5) 0 (0.0)
S. xylosus 3 (0.5) 0 (0.0)
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staphylococcal species found in clinical specimens, susceptibility
for several antimicrobials, corresponding resistance mechanisms
and, most importantly, molecular epidemiology of methicillin-
resistant staphylococci. Moreover, we studied a long time period,
16 years, to establish trends in antimicrobial resistance and
changes in genotypes.
The overall prevalence of clinical methicillin-resistant
staphylococcal isolates found in this study was 11.7%, which is
higher than the prevalence found in a similar study conducted in
Lithuania (5.3%).26 This difference could be due to a higher con-
sumption of first- and second-generation cephalosporins in
Portugal compared with Lithuania.27 However, the prevalence
of MRSA within S. aureus isolates (40.7%) and MRSP within
S. pseudintermedius (8.7%) was similar to two studies conducted
in Germany (ranging from 41.3% to 62.7% MRSA in S. aureus of
canine, feline and equine origin; and 6.3% of MRSP within isolates
belonging to the S. intermedius group).28,29 In Italy, a much
higher prevalence of MRSP was found in clinical samples
(21% of MRSP within isolates belonging to the S. intermedius
group).30 Interestingly, Germany and Portugal have similar con-
sumptions of first- and second-generation cephalosporins, but in
Italy it is higher.27 We could speculate that cephalosporins may
select for methicillin-resistant isolates, but further studies are
needed.

















Ampicillin 58.7 (54.7–62.6) 40.7 77.8 64.4 38.4 ,0.0001
Penicillin 58.7 (54.7–62.6) 40.7 77.8 64.4 38.4 ,0.0001
Amoxicillin/clavulanic acid 7.8 (5.8–10.1) 5.8 37.0 7.6 0.0 ,0.0001
Cefalexin 6.0 (4.3–8.2) 2.3 22.2 6.7 0.0 0.0002
Cefovecin 10.4 (8.2–13.1) 19.8 40.7 8.5 0.0 ,0.0001
Ceftriaxone 8.5 (6.5–11.0) 11.6 37.0 7.6 0.0 ,0.0001
Cefotaxime 8.5 (6.5–11.0) 10.5 37.0 7.9 0.0 ,0.0001
Cefoxitina 28.3 (20.2–37.6) 24.4 40.7 — — 0.1005
Oxacillinb 8.7 (6.3–11.8) — — 8.7 — —
Enrofloxacin 12.3 (9.9–15.2) 14.0 40.7 9.2 19.2 ,0.0001
Ciprofloxacin 12.3 (9.9–15.2) 14.0 40.7 9.2 19.2 ,0.0001
Levofloxacin 11.4 (9.0–14.1) 14.0 40.7 9.0 12.3 ,0.0001
Norfloxacin 12.7 (10.2–15.5) 16.3 40.7 9.2 19.2 ,0.0001
Ofloxacin 12.8 (10.3–15.7) 16.3 40.7 9.2 20.6 ,0.0001
Moxifloxacin 10.1 (7.9–12.8) 11.6 40.7 8.1 9.6 ,0.0001
Tetracycline 34.8 (31.1–38.9) 23.3 3.7 44.0 4.1 ,0.0001
Nitrofurantoin 0.5 (0.1–1.4) 0.0 0.0 0.7 0.0 0.7393
Chloramphenicol 4.6 (3.1–6.5) 1.2 3.7 6.1 0.0 0.0450
Florfenicol 0.5 (0.1–1.4) 0.0 3.7 0.5 0.0 0.0812
Gentamicin 7.6 (5.7–9.9) 11.6 0.0 8.3 1.4 0.0358
Neomycin 14.9 (12.2–17.9) 5.8 7.4 19.1 2.7 ,0.0001
Tobramycin 7.1 (5.2–9.4) 9.3 0.0 8.1 1.4 0.0735
Amikacin 0.3 (0.0–1.1) 2.3 0.0 0.0 0.0 0.0052
Kanamycin 18.7 (15.7–21.9) 12.8 3.7 23.3 2.7 ,0.0001
Streptomycin 20.6 (17.5–23.9) 8.1 7.4 26.7 2.7 ,0.0001
Erythromycin 20.1 (17.0–23.4) 25.6 11.1 22.2 4.1 0.0012
Clindamycin 17.1 (14.2–20.3) 12.8 7.4 20.6 4.1 0.0014
Fusidic acid 4.1 (2.7–6.0) 24.4 3.7 0.9 0.0 ,0.0001
Mupirocin 0.2 (0.0–0.9) 0.0 0.0 0.0 1.4 0.0534
Sulfamethoxazole/trimethoprim 13.3 (10.7–16.2) 8.1 0.0 16.4 5.5 0.0034
Sulphonamides 46.8 (43.0–50.7) 29.1 11.1 54.3 35.6 ,0.0001
Trimethoprim 16.9 (14.1–20.1) 12.8 3.7 20.0 8.2 0.0105
Rifampicin 1.9 (1.0–3.3) 3.5 0.0 1.4 4.1 0.2272
Resistance to at least one antimicrobial 79.4 (76.1–82.5) 74.4 81.5 82.7 64.4 0.0023
Resistance to at least three antimicrobials 35.0 (31.3–38.8) 34.9 25.9 39.0 13.7 0.0003
The P value refers to the association between antimicrobial resistance and staphylococcal species.
All isolates were susceptible to netilmicin, vancomycin, teicoplanin, linezolid and quinupristin/dalfopristin.
aUsed for S. aureus and CoNS.
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Most of our isolates were characterized as S. pseudintermedius,
which was expected sincemost isolates were from dogs, where this
species is the most frequently found.1 Recently, two studies evalu-
ated antimicrobial resistance in S. pseudintermedius over time and
detected trends of increasing resistance to ampicillin/amoxicillin/
penicillin, cefovecin, cefalexin, enrofloxacin, clindamycin and sulfa-
methoxazole/trimethoprim.24,25 In our study, trends of increasing
resistance to these antimicrobials were also observed, but
we detected other trends of increasing resistance, including cefoxi-
tin in S. aureus and CoNS, oxacillin in S. pseudintermedius and
ciprofloxacin, norfloxacin, ofloxacin, moxifloxacin, tetracycline,
chloramphenicol, gentamicin, neomycin, tobramycin, kanamycin,
streptomycin, erythromycin, sulphonamides and trimethoprim in
all staphylococcal groups analysed. Moreover, increasing trends of
resistance to at least one antimicrobial and multidrug resistance
were also identified, such that 35% of the staphylococcal
isolates were MDR. The most common multidrug resistance pat-
tern among the methicillin-susceptible isolates was ampicillin/
penicillin/tetracycline/sulphonamides and in methicillin-resistant
isolates it was b-lactams/fluoroquinolones/tetracycline. These
resistance profiles are in accordance with the antimicrobial
usage patterns in companion animal practice in Portugal.27 In
fact, penicillins+b-lactamase inhibitors, first- and second-
generation cephalosporins, fluoroquinolones and tetracyclines
are among the antimicrobials most used (in this order) by com-
panion animal practitioners in this country.27
Isolates from otitis were more resistant to several antimicro-
bials and more often carried the mecA gene than isolates from
pyoderma or UTI. This finding suggests that these antimicrobials
are probably being used inappropriately for the treatment of otitis.
The recommended treatment option for otitis externa is antisep-
tics; however, in some cases (e.g. ulceration and/or tympanic
membrane rupture) there is a need for administration of systemic
antimicrobial therapy and the first-line antimicrobials are
b-lactams or fluoroquinolones.31 –33 However, antimicrobials
that are used systemically for otitis are unlikely to achieve thera-
peutic concentrations within the fluid and waxy exudates of the
external canals in which the infectious organisms are har-
boured.26 Our study probably reflects the selective pressure
imposed on staphylococci in the ear by the use of these antimicro-
bials, including the higher frequency of mecA-positive staphylo-
cocci, further supporting the urgent need for more studies on
the efficacy of systemic antimicrobials for ear infections.
There are no cefoxitin or oxacillin recommended breakpoints for
S. schleiferi subsp. coagulans. However, these breakpoints are
important for diagnostic purposes, since this species is very
common in companion animals. Although we did not find mecA-
positive isolates, there are already descriptions of methicillin-
resistant S. schleiferi subsp. coagulans isolates27 and therefore
there is an urgent need to determine appropriate breakpoints for
this species.Moreover, with the increasing frequencyofMDR strains,
some antimicrobials are being suggested as second-line antimicro-
bial agents, namely florfenicol, amikacin, minocycline, doxycycline,
nitrofurantoin, topical fusidic acid or mupirocin.34–36 Even some
antimicrobials that are used daily in companion animal practice
(e.g. ampicillin, cefovecin or sulfamethoxazole/trimethoprim) do
not have clinical breakpoints determined for these species. Thus,
updated and species-specific clinical breakpoints are essential for
the appropriate selection of antimicrobials.
Interestingly, the first mecA-positive isolate detected in our
study was an MRSA isolated in 2001. ST22-IV, which represents
EMRSA-15, was the most common MRSA lineage found in this
study. This is in agreement with previous reports, which show that
there is a shared population of this lineage infecting/colonizing
Table 3. Frequency of resistance genes for the total isolates and per staphylococcal species
Resistance gene
Percentage of the














mecA 11.6 (9.2–14.3) 26.7 40.7 8.7 0.0 ,0.0001
blaZ 59.0 (55.1–62.9) 40.7 77.8 64.6 39.7 ,0.0001
erm(A) 0.8 (0.3–1.8) 4.7 3.7 0.0 0.0 ,0.0001
erm(B) 18.2 (15.3–21.4) 12.8 3.7 22.4 4.1 0.0001
erm(C) 2.4 (1.3–3.9) 11.6 7.4 0.2 2.7 ,0.0001
cat pC221 4.1 (2.7–6.0) 1.2 0.0 5.6 0.0 0.0335
aphA3 18.0 (15.1–21.3) 7.0 11.1 23.3 1.4 ,0.0001
aacA-aphD 7.6 (5.7–9.9) 11.6 3.7 8.1 1.4 0.0803
aadD 0.5 (0.0–1.0) 3.5 0.0 0.0 0.0 0.0003
aadE 16.3 (13.5–19.4) 0.0 0.0 23.1 0.0 ,0.0001
tet(K) 9.3 (7.2–11.9) 20.9 0.0 9.2 0.0 ,0.0001
tet(M) 27.5 (24.1–31.2) 4.7 3.7 37.2 4.1 ,0.0001
dfr(K) 0.2 (0.0–0.9) 0.0 0.0 0.2 0.0 0.9366
dfr(G) 7.0 (5.1–9.2) 3.5 3.7 9.0 0.0 0.0163
msrA 1.9 (1.0–3.3) 9.3 3.7 0.5 1.4 ,0.0001
mph(C) 2.2 (1.2–3.7) 10.5 3.7 0.7 1.4 ,0.0001
fusB 2.1 (1.1–3.5) 12.8 0.0 0.2 1.4 ,0.0001
fusC 0.8 (0.3–1.8) 4.7 3.7 0.0 0.0 ,0.0001
The P value refers to the association between antimicrobial resistance genes and staphylococcal species.
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humans and companion animals.37 The ST22-t032-SCCmec IV iso-
lates were negative for erm(C), while the other ST22-IV non-t032
(t2357 and t025) isolates carried the erm(C) gene. It is assumed
that the loss of this gene is associated with isolates coming from
companion animals,37 which suggests that the MRSA ST22
non-t032 isolates found in our study were acquired from humans
very recently and have thus maintained the erm(C) gene.
OnlyoneMRSA isolatewas ST398-t108-V, a livestock-associated
MRSA, and it was isolated from a dog. This isolate had 93%
ApaI-PFGE similarity to previously isolated MRSA isolates from
calves in Portugal (data not shown).38 Surprisingly, all these isolates
(from dog and calves) carried the fexA gene and were resistant to
Table 4. Risk factors and corresponding OR, CI and P value for the
occurrence of significant individual antimicrobial resistance and the mecA
gene, from logistic regression analyses conducted by animal species and
by type of infection
Risk factor Antimicrobial/gene ORa CI P
Dogsb OXA 6.4 2.2–18.5 0.0005
ENR 2.8 1.6–4.9 0.0006
CIP 2.8 1.6–4.9 0.0006
LVX 3.1 1.7–5.6 ,0.0001
NOR 3.1 1.8–5.5 ,0.0001
OFX 3.1 1.8–5.4 ,0.0001
MXF 3.1 1.7–5.7 0.0003
TET 0.3 0.2–0.6 0.0005
GEN 2.8 1.4–5.5 0.0034
TOB 3.1 1.5–6.1 0.0016
FUS 3.9 1.6–9.4 0.0030
mecA 3.0 1.7–5.4 0.0002
Otitisc FOX 3.7 1.2–11.1 0.0191
OXA 5.6 2.2–14.4 0.0004
ENR 2.4 1.3–4.4 0.0035
CIP 2.4 1.3–4.4 0.0035
LVX 2.7 1.4–5.0 0.0016
NOR 2.2 1.2–3.9 0.0077
OFX 2.1 1.2–3.7 0.0111
MXF 3.0 1.5–6.0 0.0012
mecA 5.1 2.6–10.1 ,0.0001
Otitisd ENR 2.4 1.2–4.9 0.0173
CIP 2.4 1.2–4.9 0.0173
LVX 2.6 1.2–5.4 0.0139
NOR 2.2 1.1–4.4 0.0313
OFX 2.1 1.0–4.2 0.0410
MXF 3.0 1.3–6.7 0.0071
FUS 4.2 1.4–12.9 0.0114
mecA 3.1 1.4–7.3 0.0075
CIP, ciprofloxacin; ENR, enrofloxacin; FOX, cefoxitin; FUS, fusidic acid; GEN,
gentamicin; LVX, levofloxacin; MXF, moxifloxacin; OXA, oxacillin; NOR,
norfloxacin; OFX, ofloxacin; TET, tetracycline; TOB, tobramycin.
aOR for the occurrence of isolates resistant to the antimicrobial listed, con-
sidering the risk factors of animal species (dogs versus cats) and type of
infection (otitis versus pyoderma and otitis versus UTI).
bOR relative to isolates from cats.
cOR relative to isolates from pyoderma.



























































































niversity Library user on 05 Septem
ber 2018
fluoroquinolones, which suggests that they had a similar source of
infection/colonization.38 However, the dog in our study had no his-
tory of contact with farms or farm animals and therefore this
remains to be elucidated. The MRSA ST5-t311-VI isolated from a
cat was resistant to fusidic acid and carried the fusC gene, as
was reported for one MRSA ST5-t062-VI isolated from a horse in
a previous study.22 Comparing the SmaI-PFGE profiles of these
two isolates (data not shown) revealed they had 86% similarity.
As the cat’s strain was isolated in 2001, we could not determine
whether therewas any history of contact with horses and therefore
we could not define the source of infection/colonization. However,
it is interesting to notice that several MRSA lineages are dissemi-
nated in different animal species.
The first MRSP strain was identified in Portugal in 2007, but only
in 2010 was an increase in the number of isolates detected. The
first MRSP isolates in Europe were detected in 200539 and were
ST71-II-III. Interestingly, the first MRSP strain in Portugal, isolated
in 2007, was ST196-V. Only in 2009 did the first ST71-II-III appear
in Portugal. Between 2009 and mid-2012, MRSP CC71-II-III was
the only lineage detected. Yet, in 2013–14 we observed a higher
genetic diversity among the MRSP isolates obtained, with other
MRSP lineages appearing, including a new ST (ST400) carrying
the mecA gene. The ST45-NT, ST339-NT and ST342-IV lineages
have already been described in recent studies.2,40 ST45 was the
predominant MRSP clonal lineage in Thailand and Israel and
was not typeable by SmaI-PFGE and SCCmec typing.40 This lin-
eage carried a novel pseudo-SCCmec element, CSCCmec57395,
that, besides mecA, also carried determinants of resistance to
heavy metals such as arsenic, cadmium and copper.40 It seems
that this ST has also been introduced into Europe, as the MLST
database reports that ST45 has been detected in England, the
Netherlands and now in Portugal. The new ST, ST400, does not
belong to any of the previous mecA-positive CCs, which suggests
that SCCmec has been acquired by this ST. Two of the MRSP ST400
isolates were isolated from two dogs that lived in the same ken-
nel. However, the third dog had no connection with these dogs or
the kennel, which could mean that this lineage is already spread-
ing through the dog population in Portugal.
The fexA gene was detected in three isolates (two
S. pseudintermedius and one S. aureus). The animals (three dogs)
infected with these isolates had previously been diagnosed with
an infection caused by an MDR MRSA or MRSP strain and thus flor-
fenicol (25–50 mg/kg q12h subcutaneously; Nuflorw, Merck Animal
Health, USA) was being used as a last-resort antimicrobial. The use
of florfenicol was very recently suggested as a second-line anti-
microbial agent in dogs.34 However, it seems that the use of this
antimicrobial can lead to additional acquisition of antimicrobial
resistance genes or isolates. Furthermore, one of these isolates
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Figure 1. Evolution of antimicrobial resistance over the 16 years studied (P,0.05): (a) b-lactams; (b) fluoroquinolones; (c) aminoglycosides; (d) folate
pathway inhibitors; and (e) other antimicrobials. AMC, amoxicillin/clavulanic acid; AMP, ampicillin; CEF, cefalotin; CHL, chloramphenicol; CIP, ciprofloxacin;
CLI, clindamycin; CRO, ceftriaxone; CTX, cefotaxime; CVN, cefovecin; ENR, enrofloxacin; ERY, erythromycin; FOX, cefoxitin; GEN, gentamicin; KAN,
kanamycin; LVX, levofloxacin; MXF, moxifloxacin; NEO, neomycin; NOR, norfloxacin; OFX, ofloxacin; OXA, oxacillin; PEN, penicillin; STR, streptomycin;
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Figure 2. Proportion of mecA-positive isolates over the 16 years
studied (P,0.05).
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best of our knowledge, this is the first description the cfr gene in an
S. pseudintermedius strain isolated from a dog undergoing florfeni-
col treatment. Although the strain did not exhibit resistance to line-
zolid, this is aworrisome finding, since it shows S. pseudintermedius
could be carriers of important resistance genes.
The MRSE STs found in this study were identical to those iso-
lated in humans in Portugal (community- and hospital-acquired
isolates).41 This means that MRSE isolates can circulate between
humans and animals, making these a reservoir of important
MRSE lineages. Unfortunately, there is no MLST database for
S. haemolyticus, which makes it impossible to compare our iso-
lates with other animal or even human isolates. Nevertheless, it
is important to notice that methicillin-resistant CoNS were more
frequently isolated than might be expected from previous studies
and the presence of the mecA gene was highly associated with
these isolates. Furthermore, several methicillin-resistant CoNS
exhibited a multidrug resistance pattern, suggesting that they
are reservoirs of antimicrobial resistance genes.
The results reported herein might be a biased representation
of the reality found in companion animals in Portugal, as they
were obtained from a reference laboratory that receives samples
from complicated infections observed in private practices. This
suggests that our results represent only a small part of the
staphylococcal isolates that in reality infect companion animals.
However, since our laboratory has been collecting samples since
1999, the increased frequency of antimicrobial resistance over
time reported here probably reflects what is happening in the
staphylococcal population in general. Additionally, the observed
time trend for the various antimicrobials reflects the develop-
ment of new resistant strains, but also the spread of resistant
organisms over time.
This study highlights the importance of companion animals as
reservoirs of important antimicrobial-resistant pathogens. In
2005, Heuer et al.42 underlined that the use of antimicrobial
drugs in companion animals had received little attention and
that monitoring programmes had focused solely on antimicrobial
drug consumption in food animals. Ten years later, the European
Surveillance of Veterinary Antimicrobial Consumption group
reported information on the sales of tablets by veterinary anti-
microbial class for companion animals.27 Yet, no alterations or
restrictions in antimicrobial prescription in companion animals
have been imposed so far (especially considering critically import-
ant antimicrobials). International and national guidelines on anti-
microbial use for companion animal practice are urgently needed.
Another problem that requires immediate attention is updated
and species-specific clinical breakpoints. Together, these features
will hopefully improve antimicrobial stewardship and prevent the
development of antimicrobial resistance.
The significant increase in antimicrobial-resistant and mecA-
positive isolates in recent years is worrying. Furthermore, several
isolates are MDR, which complicates antimicrobial treatment
and raises the risk of transfer to humans or human isolates.
Several clonal lineages of MRSA and MRSE circulating in human
hospitals and the community were found in this study, suggesting
that companion animals can become infected with and contrib-
ute to the dissemination of highly successful human clones.
Thus, companion animals can act as reservoirs of important
human clones, perpetuating the transmission cycle of methicil-
lin-resistant staphylococci between humans and companion
animals.
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